The Functional Cure That Took Fifty Years: What GSK's Hibsago Approval Means for Hepatitis B

For most of the past half-century, chronic hepatitis B has been a disease you managed, not one you cured. The antiviral drugs that arrived in the late 1990s and early 2000s, tenofovir and entecavir chief among them, were genuine advances. They suppressed the hepatitis B virus to undetectable levels in the blood, reduced the risk of cirrhosis and liver cancer, and extended lives. But they did not eliminate the infection. Patients who started them typically stayed on them indefinitely, because stopping treatment almost always led to viral rebound. The virus persisted in the liver, tucked inside infected cells in a form called covalently closed circular DNA, invisible to the immune system and inaccessible to the drugs that kept it quiet.

On October 21, 2026, the FDA approved Hibsago, the antisense oligonucleotide therapy developed by GSK and Ionis Pharmaceuticals, as the first treatment capable of achieving what the field calls a functional cure: undetectable levels of the virus and its surface antigen for at least 24 weeks after a finite course of treatment. The approval is narrow in scope, applying to adults with chronic hepatitis B who have been on antivirals for at least six months, have suppressed viral loads, and have not yet developed cirrhosis. But the clinical story behind it, and the implications for a disease that affects 240 million people worldwide, are considerably larger than the label suggests.

What Hibsago Actually Does

Bepirovirsen, the active molecule in Hibsago, is an antisense oligonucleotide, a short synthetic strand of nucleic acid designed to bind to hepatitis B virus RNA and trigger its degradation. Unlike the nucleoside analogues that dominate current treatment, which block viral replication but leave the underlying infection intact, bepirovirsen targets the viral RNA itself. It reduces production of all the proteins the virus makes, including hepatitis B surface antigen, the protein that the immune system needs to clear in order to achieve functional cure. By depleting surface antigen, the drug appears to allow the immune system to recognize and respond to the infection in a way that suppression alone does not enable.

The mechanism is dual. Bepirovirsen both silences viral gene expression and activates innate immune pathways, creating a combined antiviral and immunostimulatory effect. That combination is what distinguishes it from prior antisense approaches that targeted only one arm of the problem. The two Phase 3 trials supporting the approval, published in the New England Journal of Medicine, showed that roughly 20 percent of patients who received Hibsago alongside their existing antivirals achieved functional cure, defined as undetectable hepatitis B surface antigen and viral DNA for at least 24 weeks. In the placebo arms, the rate was zero. Treatment is administered via periodic injections over six months, with all but the first dose self-administered at home.

The Weight of the Number

A 20 percent functional cure rate is not a number that should be dismissed as modest. The appropriate comparison is not to some hypothetical perfect therapy but to the existing standard of care, which produces functional cure in fewer than one percent of patients per year on long-term antiviral therapy. For a disease that has resisted curative approaches for decades, a treatment that achieves durable viral clearance in one in five patients represents a genuine discontinuity from what came before.

The 80 percent who do not achieve functional cure are not left worse off. They remain on their existing antivirals, which continue to suppress the virus effectively. Hibsago is an addition to the treatment landscape, not a replacement for it. The question the field will now work to answer is whether the 20 percent responder rate can be improved through patient selection, combination approaches, or longer treatment courses. The biology of why some patients clear the virus and others do not is not yet fully understood, and that gap represents both a scientific challenge and a commercial opportunity for the programs that follow.

The Safety Caveat That Will Shape Adoption

The FDA's prescribing information for Hibsago carries a warning for sudden spikes in liver inflammation and low platelet counts, side effects that require weekly or bi-weekly laboratory monitoring throughout treatment. That monitoring burden is real, and analysts at Jefferies have noted it may slow adoption outside of specialty hepatology centers, at least initially. The requirement for regular blood tests adds a logistical layer that does not exist with the oral antivirals patients are already taking, and it will require careful patient counseling and practice infrastructure to manage at scale.

GSK has not yet disclosed the drug's list price, indicating it will be set following completion of pricing and reimbursement discussions with payers. That timing is unusual and suggests the company is navigating a complex access environment. Jefferies analysts project peak annual sales of approximately $3 billion, a figure that reflects both the size of the addressable population and the constraints imposed by the narrow label and monitoring requirements. Whether that projection proves accurate will depend heavily on how payers respond to a drug that offers a finite treatment course and the possibility of cure, a value proposition that is genuinely different from the chronic maintenance model that has defined hepatitis B treatment economics for two decades.

The Broader Implications for Infectious Disease

The Hibsago approval is also a milestone for the antisense oligonucleotide platform more broadly. Ionis Pharmaceuticals, which developed the underlying chemistry and licensed it to GSK, has spent decades building the case that RNA-targeting medicines can address diseases that small molecules and antibodies cannot. The hepatitis B approval is the most prominent infectious disease application of that platform to date, and it demonstrates that antisense approaches can achieve durable biological effects in a viral context, not just in the genetic and metabolic diseases where the technology has been most extensively validated.

The drug has already been approved in Japan and is under regulatory review in China and Europe. For the 240 million people living with chronic hepatitis B globally, the majority of whom are in Asia and sub-Saharan Africa, the path to access will depend on how those reviews proceed and how pricing is structured for lower-income markets. The disease burden is concentrated in populations where the commercial dynamics of specialty hepatology are very different from those in the United States. How GSK navigates that tension will be one of the more consequential decisions the company makes as it builds out the Hibsago franchise.

What the FDA's approval establishes today is that chronic hepatitis B, a disease that has been managed but not cured for fifty years, now has a treatment capable of achieving functional cure in a meaningful fraction of patients. That is not a minor refinement of existing care. It is a different kind of outcome altogether, and for the patients who achieve it, the difference between managing a lifelong infection and clearing it is not a statistical abstraction. It is the difference between a disease that defines the rest of your life and one that does not.